XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 35.4% in February

XBiotech Inc. (NASDAQ:XBITGet Free Report) saw a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 537,500 shares, an increase of 35.4% from the February 14th total of 397,000 shares. Based on an average trading volume of 36,700 shares, the days-to-cover ratio is presently 14.6 days. Approximately 2.7% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on XBiotech in a report on Thursday, February 15th. They issued a “sell” rating for the company.

View Our Latest Analysis on XBiotech

Institutional Investors Weigh In On XBiotech

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in XBiotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 881,511 shares of the biopharmaceutical company’s stock worth $3,526,000 after acquiring an additional 9,068 shares during the period. BlackRock Inc. boosted its position in shares of XBiotech by 10.5% during the second quarter. BlackRock Inc. now owns 289,847 shares of the biopharmaceutical company’s stock worth $1,722,000 after buying an additional 27,651 shares during the period. Millennium Management LLC boosted its position in shares of XBiotech by 1,602.0% during the second quarter. Millennium Management LLC now owns 284,679 shares of the biopharmaceutical company’s stock worth $1,603,000 after buying an additional 267,953 shares during the period. Credit Suisse AG boosted its position in shares of XBiotech by 16.6% during the third quarter. Credit Suisse AG now owns 263,708 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 37,561 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of XBiotech by 11.7% during the second quarter. Geode Capital Management LLC now owns 173,181 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 18,098 shares during the period. 11.45% of the stock is currently owned by hedge funds and other institutional investors.

XBiotech Trading Down 0.3 %

NASDAQ:XBIT opened at $6.31 on Thursday. XBiotech has a 12 month low of $3.05 and a 12 month high of $7.24. The stock has a 50 day moving average of $5.45 and a two-hundred day moving average of $4.61.

About XBiotech

(Get Free Report)

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.

Further Reading

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.